氨甲环酸用于产后出血:随机对照试验的系统综述与个体患者数据Meta分析
该系统综述与个体患者数据Meta分析纳入5项随机对照试验共54 404名分娩女性,评估氨甲环酸对危及生命的出血及血栓栓塞事件的影响。结果显示氨甲环酸组危及生命的出血发生率为0.65%,安慰剂组为0.85%(合并OR 0.77,95%CI 0.63-0.93;p=0.008),血栓栓塞事件两组无显著差异(合并OR 0.96,95%CI 0.65-1.41;p=0.82)。作者不推荐对所有分娩女性使用氨甲环酸,但认为高死亡风险女性可在诊断为产后出血前考虑使用。
要点
- 氨甲环酸降低分娩女性危及生命的产后出血风险(合并OR 0.77,95%CI 0.63-0.93)。
- 氨甲环酸未增加血栓栓塞事件风险(合并OR 0.96,95%CI 0.65-1.41)。
- 作者不推荐对所有分娩女性使用氨甲环酸,高死亡风险女性可考虑在诊断产后出血前使用。
核心结论
- 氨甲环酸降低危及生命的产后出血风险。
- 未发现氨甲环酸增加血栓形成风险的证据。
- 作者不推荐对所有分娩女性使用氨甲环酸,但认为高死亡风险女性可在诊断为产后出血前考虑使用。
研究设计与样本
- 系统综述与个体患者数据Meta分析,检索WHO国际临床试验注册平台从建库至2024年8月4日的随机对照试验。
- 纳入标准为前瞻性注册、安慰剂对照、纳入超过500名女性、随机序列生成与分配隐藏低偏倚风险的试验。
- 共分析5项试验的54 404名女性,其中4项试验43 409名女性获得个体患者数据,1项试验10 995名女性获得聚合数据。
- 所有试验均为低偏倚风险。
- 研究注册于PROSPERO,CRD42022345775。
主要发现
- 危及生命的出血在氨甲环酸组27 300名女性中发生178例(0.65%),安慰剂组27 093名女性中发生230例(0.85%)(合并OR 0.77,95%CI 0.63-0.93;p=0.008)。
- 无证据表明氨甲环酸的效果因危及生命的出血基础风险、分娩方式、中重度贫血或给药时机(产后出血诊断前后)而异。
- 血栓栓塞事件在氨甲环酸组26 571名女性中发生50例(0.2%),安慰剂组26 373名女性中发生52例(0.2%),两组无显著差异(合并OR 0.96,95%CI 0.65-1.41;p=0.82)。
- 亚组分析未发现显著异质性。
关键数值与推荐
- 危及生命的出血:氨甲环酸组178/27 300(0.65%) vs 安慰剂组230/27 093(0.85%),合并OR 0.77(95%CI 0.63-0.93;p=0.008)。
- 血栓栓塞事件:氨甲环酸组50/26 571(0.2%) vs 安慰剂组52/26 373(0.2%),合并OR 0.96(95%CI 0.65-1.41;p=0.82)。
临床怎么用
- 作者不推荐对所有分娩女性使用氨甲环酸。
- 作者认为高死亡风险女性可在诊断为产后出血前考虑使用氨甲环酸。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tranexamic acid is a recommended treatment for women with a clinical diagnosis of postpartum haemorrhage, but whether it can prevent bleeding is unclear. We conducted a systematic review and individual patient data (IPD) meta-analysis of randomised controlled trials to assess the effects of tranexamic acid in women giving birth. METHODS: In this systematic review and IPD meta-analysis, we searched the WHO International Clinical Trials Registry Platform from database inception to Aug 4, 2024 for randomised trials that assessed the effects of tranexamic acid in women giving birth. Trials were eligible if they were prospectively registered, placebo-controlled, included more than 500 women, and had a low risk of bias for random sequence generation and allocation concealment. IPD were requested from the trial investigators. The primary outcomes were the numbers of women with life-threatening bleeding and thromboembolic events. We used a one-stage model to analyse the data and explored whether the effect of tranexamic acid varied by the underlying risk of life-threatening bleeding, type of birth, presence of moderate or severe anaemia, or timing of administration (before or after a diagnosis of postpartum haemorrhage). This study is registered with PROSPERO, CRD42022345775. FINDINGS: We analysed data on 54 404 women from five trials. We obtained IPD for 43 409 women from four trials and aggregate data on 10 995 women from one trial. All trials had a low risk of bias. Life-threatening bleeding occurred in 178 (0·65%) of 27 300 women in the tranexamic acid group versus 230 (0·85%) of 27 093 women in the placebo group (pooled odds ratio [OR] 0·77 [95% CI 0·63-0·93]; p=0·008). There was no evidence that the effect of tranexamic acid varied by the underlying risk of life-threatening bleeding, type of birth, presence of moderate or severe anaemia or timing of administration. No significant difference was identified between tranexamic acid and placebo groups with regard to thromboembolic events: 50 (0·2%) of 26 571 women in the tranexamic acid group had fatal or non-fatal thromboembolic events versus 52 (0·2%) of 26 373 women in the placebo group (pooled OR 0·96 [0·65-1·41]; p=0·82) with no significant heterogeneity identified in the subgroup analyses. INTERPRETATION: Tranexamic acid reduces the risk of life-threatening postpartum bleeding. We found no evidence that tranexamic acid increases the risk of thrombosis. Although we do not recommend the use of tranexamic acid in all women giving birth, consideration should be given to its use before a diagnosis of postpartum haemorrhage in women at high risk of death. FUNDING: The Bill & Melinda Gates Foundation.
引用
- Ker K, Sentilhes L, Shakur-Still H, et al. Tranexamic acid for postpartum bleeding: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet. 2024. PMID: 39461793. doi:10.1016/S0140-6736(24)02102-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。